Dissolvable Hydrogel Dressing for the Treatment of Burns

用于治疗烧伤的可溶性水凝胶敷料

基本信息

项目摘要

 DESCRIPTION: This application describes the synthesis, characterization, and evaluation of a hydrogel dressing that dissolves and can be easily removed from the wound surface of a patient with second degree burns with no further trauma. Burns are one of the most common and devastating forms of trauma. Each year, more than 300,000 people die from fire-related burn injuries and millions suffer from burn-related disabilities and disfigurements with psychological, social, and economic effects on both the survivors and their families. Dressing removal is reported to be the time of most pain (after the burn itself) and opioids continue to be the mainstay of treatment for the burn patient. The duration of a burn dressing change in a typical injury requiring ICU/OR level care is often at least 60 minutes with induction of general anesthesia, which can extend to more than three hours depending on the case. At present, all clinically approved available dressings adhere to the wound surface so that each change of dressing leads to traumatization of newly formed tissues on the outer layer of the body's surface, delayed healing, and great personal suffering for the injured patient. The application describes a thiol- terminated dendron and a bifunctional NHS-activated PEG that react with each other to form a thioester-linked hydrogel dressing that can be subsequently dissolved by exposure of an aqueous thiol solution via a thiol- thiolester exchange mechanism. The proposed experiments will test the hypothesis that a hydrogel- based, dissolvable burn dressing will provide a barrier to infection, promote wound healing, and be easily removable on demand. Importantly, it presents preliminary data demonstrating the synthesis, characterization, and performance of a dissolvable hydrogel dressing prototype. The specific aims of this four- year application are: Aim 1: Synthesize and characterize a series of hydrogel burn dressings; Aim 2: Determine the in vitro toxicity and biocompatibility, as well as in vivo compatibility after subcutaneous implantation of the dissolvable dressing; and Aim 3: Evaluate the efficacy of the dissolvable dressing in vivo.
 产品说明:本申请描述了水凝胶敷料的合成、表征和评价,该水凝胶敷料可溶解并可容易地从二度烧伤患者的伤口表面去除,而不会造成进一步的创伤。烧伤是最常见和最具破坏性的创伤形式之一。每年有超过30万人死于与火灾有关的烧伤,数百万人患有与烧伤有关的残疾和毁容,对幸存者及其家人造成心理、社会和经济影响。据报告,敷料移除是最疼痛的时间(烧伤本身之后),阿片类药物仍然是烧伤患者治疗的主要药物。在需要ICU/OR级别护理的典型损伤中,烧伤敷料更换的持续时间通常至少为60分钟,并伴有全身麻醉诱导,根据情况可能延长至3小时以上。目前,所有临床上批准的可用敷料都粘附在伤口表面上,使得敷料的每次更换都会导致身体表面外层上新形成的组织的创伤、延迟愈合以及受伤患者的巨大个人痛苦。本申请描述了硫醇封端的树枝化基元和双官能NHS活化的PEG,它们彼此反应以形成硫酯连接的水凝胶敷料,该水凝胶敷料随后可以通过经由硫醇-硫酯交换机制暴露于硫醇水溶液而溶解。所提出的实验将检验以下假设:基于水凝胶的可溶解烧伤敷料将提供感染屏障,促进伤口愈合,并且可根据需要容易地移除。重要的是,它提供了初步数据,证明了可溶解水凝胶敷料原型的合成、表征和性能。本申请为期4年,具体目标为:目标1:合成和表征一系列水凝胶烧伤敷料;目标2:确定可溶解敷料的体外毒性和生物相容性,以及皮下植入后的体内相容性;目标3:评价可溶解敷料的体内有效性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK W. GRINSTAFF其他文献

MARK W. GRINSTAFF的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK W. GRINSTAFF', 18)}}的其他基金

R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma
R21:一种用于治疗鳞状细胞肺癌的新型抗体药物偶联物
  • 批准号:
    10510002
  • 财政年份:
    2022
  • 资助金额:
    $ 39.18万
  • 项目类别:
R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma
R21:一种用于治疗鳞状细胞肺癌的新型抗体药物偶联物
  • 批准号:
    10671669
  • 财政年份:
    2022
  • 资助金额:
    $ 39.18万
  • 项目类别:
The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation
缺失受体的难题:通过药物受体调节增强功效
  • 批准号:
    10708018
  • 财政年份:
    2022
  • 资助金额:
    $ 39.18万
  • 项目类别:
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder
缓释松弛素2治疗肩周炎
  • 批准号:
    10443323
  • 财政年份:
    2022
  • 资助金额:
    $ 39.18万
  • 项目类别:
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder
缓释松弛素2治疗肩周炎
  • 批准号:
    10669219
  • 财政年份:
    2022
  • 资助金额:
    $ 39.18万
  • 项目类别:
Translational Research in Biomaterials
生物材料转化研究
  • 批准号:
    10259674
  • 财政年份:
    2020
  • 资助金额:
    $ 39.18万
  • 项目类别:
A novel approach for reversal of autophagic defects using lysosome-targeted nanoparticles
使用溶酶体靶向纳米颗粒逆转自噬缺陷的新方法
  • 批准号:
    9914192
  • 财政年份:
    2019
  • 资助金额:
    $ 39.18万
  • 项目类别:
A novel approach for reversal of autophagic defects using lysosome-targeted nanoparticles
使用溶酶体靶向纳米颗粒逆转自噬缺陷的新方法
  • 批准号:
    9752911
  • 财政年份:
    2019
  • 资助金额:
    $ 39.18万
  • 项目类别:
R21: Acidic Nanoparticles for Restoration of Autophagy in Age-associated NAFLD
R21:酸性纳米颗粒用于恢复年龄相关性 NAFLD 中的自噬
  • 批准号:
    9902306
  • 财政年份:
    2019
  • 资助金额:
    $ 39.18万
  • 项目类别:
Synthesis, Characterization, and Evaluation of Polymeric Tissue Lubricants
聚合物组织润滑剂的合成、表征和评估
  • 批准号:
    8886944
  • 财政年份:
    2014
  • 资助金额:
    $ 39.18万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 39.18万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 39.18万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 39.18万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 39.18万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 39.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 39.18万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 39.18万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 39.18万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 39.18万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 39.18万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了